Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Fast Is The Hutchinson-Gilford Progeria Syndrome (HGPS) Market Expected to Grow Between 2025 And 2029?
The market size for Hutchinson-Gilford Progeria Syndrome (HGPS) has seen significant growth in recent times. It is projected to increase from $97.63 billion in 2024 to $106.25 billion in 2025, indicating a Compound Annual Growth Rate (CAGR) of 8.8%. Factors contributing to this growth during the historical period include heightened awareness of rare gene abnormalities, a rise in funds dedicated to Progeria research, the expansion of genetic testing, an increase in government-led initiatives tackling rare diseases, and a global increase in the prevalence of genetic disorders.
The market size for Hutchinson-Gilford Progeria Syndrome (HGPS), is projected to witness substantial growth in the coming years, reaching a staggering$147.88 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 8.6%. The expansion during the forecast period is projected to be spurred by factors such as increased budget allotment for research and development of innovative treatments, the escalating incidence of progeria, larger worldwide healthcare spending, growing adoption of innovative therapeutic strategies and heightened demand for early detection. The forecast period will also witness significant trends like technological innovation, the creation of targeted therapies, advancements in Next-Generation Sequencing (NGS) technologies, biomarker development, and improvements in drug delivery systems.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21205&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Hutchinson-Gilford Progeria Syndrome (HGPS) Market?
The enhanced financial support for the discovery and development of innovative treatments is touted to fuel the expansion of the hutchinson-gilford progeria syndrome (HGPS) market. The funds channeled towards research and development form a key focus in the quest to push the boundaries of scientific knowledge and technological solutions. This increased allocation towards research and development is largely due to a surge in the quest for innovative treatment options and governmental backing for progress in healthcare. Greater funding support boosts the progression of hutchinson-gilford Progeria Syndrome treatments through the promotion of clinical trials and the development of groundbreaking therapies. This support aids in deciphering the genetic basis of the disease, paving the way for designing targeted solutions. To illustrate, the Office for National Statistics, a UK-based government agency, revealed in April 2024 that in 2022, there was a 10.5% increase in the UK government’s net spend on research and development (R&D), with funding escalating to £15.5 billion ($17.59) from an initial £14.0 billion ($15.88) in 2021. Hence, this significant boost in investment for the discovery and development of new therapies is predominantly steering the growth of the hutchinson-gilford progeria syndrome (HGPS) market.
Which Key Market Segments Comprise the Hutchinson-Gilford Progeria Syndrome (HGPS) Market and Drive Its Revenue Growth?
The hutchinson-gilford progeria syndrome (hgps)market covered in this report is segmented –
1) By Treatment Type: Farnesyltransferase Inhibitors (Zokinvy (Lonafarnib)); Low-dose Aspirin; Physical And Occupational Therapy; Hearing Aids; Genetic Counseling; Other Treatment Types
2) By Route Of Administration: Oral; Injectable; Intravenous; Transdermal
3) By Mechanism Of Action: Antisense Oligonucleotides; Crispr-cas9 Gene Editing; Rna Interference; Targeted Drug Delivery Systems
4) By End-User: Hospitals; Specialty Clinics; Academic And Research Institutes; Other End-Users
Subsegments:
1) By Farnesyltransferase Inhibitors (Zokinvy (Lonafarnib)): Monotherapy With Lonafarnib; Combination Therapy With Other Drugs
2) By Low-dose Aspirin: Cardiovascular Protection; Anti-inflammatory Therapy
3) By Physical And Occupational Therapy: Mobility Support And Rehabilitation; Joint And Bone Health Management; Adaptive Equipment For Daily Activities
4) By Hearing Aids: Conventional Hearing Aids; Bone-Anchored Hearing Aids (BAHA); Cochlear Implants
5) By Genetic Counseling: Family Genetic Testing; Genetic Risk Assessment; Prenatal Counseling And Guidance
6) By Other Treatment Types: Stem Cell Therapy; Gene Editing and Therapy; Nutritional Support And Management
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21205&type=smp
Which Areas Are Leading Regions in the Hutchinson-Gilford Progeria Syndrome (HGPS) Market Expansion Across the Globe?
North America was the largest region in the hutchinson-gilford progeria syndrome (HGPS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hutchinson-gilford progeria syndrome (HGPS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Strategic Trends Steering theHutchinson-Gilford Progeria Syndrome (HGPS) Market Direction?
Key players in the hutchinson-gilford progeria syndrome (HGPS) market are concentrating their efforts on creating sophisticated farnesyltransferase inhibitors to enhance treatment effectiveness and slow the progression of the disease in patients. These inhibitors act by blocking the action of farnesyltransferase, an enzyme that plays a role in protein modification and hinders abnormal cell growth and premature aging. In July 2022, Eiger BioPharmaceuticals, an American biopharmaceutical entity, was awarded marketing permission from the European Commission for Zokinvy. This signifies the first and only hutchinson-gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PL) treatment authorized in Europe for children and young adults. Clinical trials demonstrated that Zokinvy, an orally administered disease-modifying drug, can reduce the death risk in children by 72% and extend lifespan by an average of 4.3 years. The marketing authorization given by the European Commission is applicable in all 27 EU member countries, along with Iceland, Liechtenstein, and Norway.
View the full report here:
How Is the Hutchinson-Gilford Progeria Syndrome (HGPS) Market Conceptually Defined?
Hutchinson-Gilford Progeria Syndrome (HGPS), commonly known as progeria, is an extremely rare and fatal genetic disorder that causes accelerated aging in children. It is caused by mutations in the LMNA gene, leading to symptoms such as growth delays, hair loss, premature wrinkling of the skin, and cardiovascular issues. The average life expectancy for individuals with progeria is approximately 14.5 years.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21205
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model